Viyash Viyash Scientific Limited (formerly Sequent Scientific Limited) will host a conference call with analysts and investors on Wednesday, August 12, 2026, at 3:30 PM IST to discuss its financial results for the quarter ended June 30, 2026. The announcement, made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides stakeholders with a direct channel to review the company’s performance in Q1FY27.

The conference call aims to provide clarity on the company’s operational and financial trajectory for the initial quarter of the fiscal year. By engaging directly with market participants, management intends to address queries regarding revenue generation, cost structures, and strategic initiatives undertaken during the period. This transparency is critical for investors assessing the company’s near-term outlook and long-term growth potential in the scientific equipment and services sector.

Key leadership figures from Viyash Scientific Limited are confirmed to participate in the discussion. Dr. Hari Babu Bodepudi, Managing Director & Group CEO, will lead the session, providing overarching strategic context. He will be joined by Mr. Rajaram Narayanan, Executive Director and CEO – Animal Health, who is expected to elaborate on segment-specific performance. Mr. Ramakant Singani, Chief Financial Officer, will likely address the detailed financial metrics, cash flow dynamics, and balance sheet health presented in the quarterly filing.

Conference Call Details

Participants can access the call via the provided dial-in numbers. Early registration is facilitated through a Diamond Pass link available on the company’s investor relations portal.

The details of the conference call have been submitted to both BSE Limited and the National Stock Exchange of India Limited. The information is also publicly available on the Investors Section of the company’s website at www.viyash.com . Yoshita Vora, Company Secretary & Compliance Officer, signed the intimation letter dated August 3, 2026, ensuring regulatory compliance.

What This Means for Investors

The scheduling of this earnings call marks a standard but significant step in the corporate reporting cycle. For investors, the primary value lies in the qualitative commentary that accompanies the quantitative data. While the financial statements provide the hard numbers, the management’s narrative during the call often reveals insights into order book visibility, supply chain challenges, or shifts in customer demand that are not immediately apparent from the raw figures. Analysts will closely monitor any guidance provided for the remainder of FY27, particularly regarding margin sustainability and capital expenditure plans.

Alivira Animal Health Limited, a step-down wholly owned subsidiary of Viyash Scientific , executed a Sale and Purchase Agreement (SPA) on July 21, 2026, to acquire 100% of the issued and outstanding share capital of BioForLife Italia S.r.l. The acquisition, valued at a base aggregate consideration of approximately EUR 16.976 million, marks a strategic expansion for the company into the Italian market. The transaction terms include a revised mechanism for the deferred consideration, which is now linked to specified contractual-continuation conditions.

Transaction Structure

The financial breakdown of the acquisition involves a total consideration of approximately EUR 16.976 million, subject to adjustments based on the net financial position of the target entity. The payment structure is divided into two primary components, ensuring a portion of the value is tied to future performance or conditions.

Conditions and Approvals

The completion of this acquisition is contingent upon receiving necessary regulatory approvals. Specifically, the transaction requires the receipt of applicable Italian Foreign Direct Investment (FDI) clearance and Golden Power clearance. Additionally, the satisfaction or valid waiver of other conditions specified in the SPA is mandatory before the deal can be finalized.

Background and Disclosures

This development follows a previous disclosure made on June 8, 2026, regarding the proposed acquisition. While the deferred consideration mechanism has been revised, the company stated that all other material details disclosed in the earlier communication remain unchanged. The execution of the definitive SPA was communicated to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.